XXVI INTERNATIONAL BILE ACID MEETING: BILE ACIDS IN HEALTH AND DISEASE 2022 - Symposium 229 AMSTERDAM, THE NETHERLANDS - Falk Foundation
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
XXVI INTERNATIONAL
BILE ACID MEETING:
BILE ACIDS IN HEALTH
July 8-9, 2022
AND DISEASE 2022
Symposium 229
AMSTERDAM, THE NETHERLANDS
ATION
APPLIC
FOR CME
CRED ITS
ITTED
SUBMPreface ................................................................................................... 2
Scientific Program ............................................................................. 4
Adolf Windaus Award ...................................................................... 11
List of Speakers, Moderators and Scientific Organizers ..... 14
Posters ................................................................................................... 17
Information ........................................................................................... 18
ATION
APPLIC An application has been made to the UEMS EACCME®
FOR CMES for CME accreditation of this event. The number of credits
CRED IT
ITTED
SUBM awarded will be printed in the final program.
1PREFACE Since the last International Bile Acid Meeting in Dublin in 2018, the field of bile acid research has continued to flourish. New insights have been gained into the role of bile acid signaling in the liver and intestine, the role of bile acids and their receptors in the gut liver axis, bile acid microbiome interactions and HCC development. FXR has evolved as a target not only for cholestatic liver disease, but more recently also for NASH. Furthermore, inhibitors of bile acid transporters ASBT and NTCP have recently been approved for treatment of progressive familial intra- hepatic cholestasis (PFIC), cholestatic pruritus in Alagille’s syndrome as well as chronic HBV/HDV coinfection. The XXVI International Bile Acid Meeting will be dedicated to both, basic and clinical aspects of bile acid research with focus on the role of bile acid transport and signaling in health and disease, the interaction of bile acids with the microbiome and the role of bile acids in tumor development. Novel aspects of thera- peutic strategies using bile acid derivatives, bile acid receptor agonists or bile acid transporter inhibitors represent another focus of this con- ference. The latest findings will be presented by leading scientists and clinicians in these fields. During the symposium a poster session will also take place. In line with the tradition of the International Bile Acid Meet- ings some of the best poster abstracts will be selected by the scientific committee and the authors will be invited for oral presentations. The organizers of the XXVI International Bile Acid Meeting look forward to welcome you in Amsterdam. Dieter Häussinger (Chairman of the Organizing Committee) 2
XXVI INTERNATIONAL BILE ACID MEETING:
BILE ACIDS IN HEALTH AND DISEASE 2022
JULY 8-9, 2022
Scientific Organization: Call for Posters:
Prof. Dr. Dieter Häussinger A poster session will be held.
Department of Internal Medicine For details see page 17.
Clinic of Gastroenterology,
Hepatology and Infectious Diseases Start of Registration:
Heinrich-Heine-University Thursday, July 7, 2022
Moorenstr. 5 10:00 – 18:00 h
40225 Düsseldorf at the congress office
Telephone: +49-221-811-7569
Telefax: +49-211-811-8838 Poster Session Set-up:
E-mail: haeussin@uni-duesseldorf.de Friday, July 8, 2022
10:00 - 11:30
Scientific Co-Organization:
Ulrich Beuers, Amsterdam Publication Date of the Final
Verena Keitel, Magdeburg Program:
Michael Trauner, Vienna July 2022
Congress Venue: The final program will be
Beurs van Berlage available on the website
Damrak 243 www.falkfoundation.org one week
1012 ZJ Amsterdam before the start of the symposium.
The Netherlands
For admission to scientific events
your name badge should be clearly
visible. Accompanying persons are
not permitted during the conference
at any time.
3Friday, July 8, 2022
11:30 Welcome
Dieter Häussinger, Duesseldorf
SESSION I
Bile acid signalling
Chairs: Ulrich Beuers, Amsterdam; Dieter Häussinger, Duesseldorf
11:40 The FXR cistrome and transcriptome
Martin Wagner, Graz
12:00 An untargeted metabolomic screen for pruritogens that cause
cholestasis-associated itch
Ronald P.J. Oude Elferink, Amsterdam
12:20 Oral poster presentation
N. N.
12:40 TGR5 in biliary disease
Verena Keitel, Magdeburg
13:00 Transport mechanism and influence of bile acids on transport of
ABCB4 Lutz Schmitt, Duesseldorf
13:20 Oral poster presentation
N. N.
13:40 Lunch break with poster session
4Friday, July 8, 2022
SESSION II
Microbiome and bile acid interaction
Chairs: David D. Moore, Berkeley; N. N.
14:30 Novel bile acid synthesis pathways promote longevity
N. N.
14:50 Microbiota and bile acid interaction in alcohol-associated liver
disease
Bernd Schnabl, La Jolla
15:10 Shaping T-cell responses through interplay of microbiota and
bile acids
Clarissa Campbell, Wien
15:30 Bile acids, T cells and inflammatory bowel disease
David D. Moore, Berkeley
15:50 Coffee break with poster session
ADOLF WINDAUS AWARDS
16:10 Presentation of Adolf Windaus Awards (2020 and 2022)
Dieter Häussinger, Duesseldorf
16:20 Windaus Award 2020 lecture
16:40 Adolf Windaus Award 2022 lecture
5Friday, July 8, 2022
SESSION III
Bile acid transport and signalling in health and disease I
Chairs: Peter Fickert, Graz; Ronald P. J. Oude Elferink, Amsterdam
17:00 An integrated framework of bile flux: from solute diffusion to
bile flow
Jan G. Hengstler, Dortmund
17:20 Bile acid transport and metabolism in a mouse model with
humanized bile acid composition
Paul A. Dawson, Atlanta
17:40 Novel insights into PFIC1/PFIC2 course and long-term effects of
therapeutic interventions
Richard J. Thompson, London
18:00 Bile acid levels, UDCA and fetal outcome: novel insights
Catherine Williamson, London
18:20 Biliary repair using organoids technologies
Fotios Sampaziotis, Cambridge
18:40 Networking with light refreshments
6Saturday, July 9, 2022
SESSION IV
Bile acid transport and signalling in health and disease II
Chairs: Paul A. Dawson, Atlanta; Hanns-U. Marschall, Gothenburg
9:00 NTCP inhibition as therapeutic option in HBV/HDV
Stefan Urban, Heidelberg
9:20 NCTP deficiency ameliorates steatohepatitis
Stan van de Graaf, Amsterdam
9:40 Oral poster presentation
N. N.
10:00 Bile acid pool alterations in the enterohepatic circulation and
NASH development
Isabell Leclercq, Leuven
10:20 Coffee break with poster session
7Saturday, July 9, 2022
SESSION V
Bile acids and tumor development
Chairs: Jose J. G. Marin, Salamanca; Michael Trauner, Vienna
10:50 Bile acids, bile acid signalling and hepatobiliary tumor development
N. N.
11:10 Taurocholate promotes invasive growth of esophageal
adenocarcinoma cells and cancer stem cell expansion via
S1PR2-mediated YAP activation
Huiping Zhou, Richmond
11:30 FXR agonism inhibits intestinal cancer stem cell proliferation
and CRC progression
Ronald M. Evans, La Jolla
11:50 Oral poster presentation
N. N.
12:10 Presentation of Poster Awards
12:30 Lunch break with poster session
8Saturday, July 9, 2022
SESSION VI
Bile acid receptors and bile acid signalling as therapeutic targets I
Chairs: Stephen J. Keely, Dublin; Verena Keitel, Magdeburg
13:30 A defective HCO3-umbrella may foster biliary injury in
IgG4-related cholangitis
Toni Herta, Leipzig
13:50 Immunometabolic modulatory role of NorUDCA (norucholic
acid) for treatment of liver diseases and beyond
Michael Trauner, Vienna
14:10 FXR isoforms differentially regulate energy metabolism: potential
impact on NASH treatment efficacy
Saskia van Mil, Utrecht
14:30 Oral poster presentation
N. N.
14:50 Coffee break with poster session
9Saturday, July 9, 2022
SESSION VII
Bile acid receptors and bile acid signalling as therapeutic targets II
Chairs: Olivier Chazouilleres, Paris; N. N.
15:20 UDCA, FXR and PPAR agonists in PBC treatment
Olivier Chazouilleres, Paris
15:40 Fibrates for itch in fibrosing cholangiopathies
Ulrich Beuers, Amsterdam
16:00 New synthetic UDCA derivatives that exert selective HDC6
inhibitory activity and improve polycystic liver disease
pathogenesis
Francisco J. Caballero-Camino, San Sebastian
16:20 Oral poster presentation
N. N.
16:40 Closing Remarks
Dieter Häussinger, Duesseldorf
10ADOLF WINDAUS (1876-1959)
Adolf Windaus was born on Christmas Day in 1876 in Berlin,
where his father owned a factory. Even as a young student
in the Berlin gymnasium, he was fascinated by the epochal
discoveries of Koch and Pasteur, and by his 18th birthday he
had decided on a scientific career. He entered medical
school, taking his pre-clinical year at the University of
Freiburg and his clinical years in Berlin. However, he soon
realized, especially during the lectures of Emil Fischer, that
biological processes could be understood only when the
chemical structure of organisms was known. Therefore, as
soon as he had finished medical school, he returned to
Freiburg to study chemistry under the supervision of Heinrich Kiliani. In 1899, he
completed his first research project which dealt with the chemical composition
of digitalis. He then spent two years in compulsory military service in Berlin.
During this time he also worked in the laboratory of Emil Fischer, carrying out
studies on derivatives of aniline. On completing his military service, Windaus
returned to the University of Freiburg where he began his life-long work on the
structure of cholesterol. His thesis, which qualified him for the position of do-
cent, had the simple title „Über Cholesterin“. The choice of this research topic
originated from Windaus‘ logical belief that any substance which was so widely
distributed in animal and plant tissues must have an important biological
function, and that understanding of its structure and function might lead to
unifying concepts, a hypothesis he would subsequently prove so brilliantly. In
addition to initiating studies on cholesterol, he and his colleague Knoop soon
discovered that an amino acid containing the imidazole ring, histidine, was
present in proteins, and could be decarboxylated to give histamine. The discovery
of histamine opened a vast area of pharmacological research.
In 1913, Adolf Windaus accepted a call to direct the prestigious Institute of
Medical Chemistry in Innsbruck, Austria, where earlier Pregl had founded
microanalytical chemistry. Two years later, in 1915, he was called to be Director
of the Chemical Laboratories of the University of Göttingen, laboratories rich
in tradition since the time of Wöhler. Here, he could pursue his work on eluci-
dating the structure of cholesterol in a series of integrated investigations that
were truly Herculean in scope. In the year 1919 a most significant discovery
was made. Windaus found that coprostane could be oxidized to cholanic acid.
With the knowledge of this transformation, came the realization of the close
structural similarity of cholesterol and bile acids; one could now apply the
existing knowledge of cholesterol structure to that of bile acids and that of
bile acids to cholesterol. The work of elucidating the exact structure of the
condensed steroid rings of steroids was extraordinarily difficult. To understand
11the structural isomerism of the A / B ring juncture, it was necessary to study the simplest model compounds, cis and trans decalin. This was done with Hueckel, who later became one of the world‘s greatest physical chemists. In the twenties, Adolf Windaus, with his pupils, established the relationships between cholesterol and other important steroids such as sitosterol, the sapo- nins, and the various classes of cardiac steroids. He showed that all shared the cyclopentanophenanthrene nucleus. Inspired by Windaus, his pupil Butenandt isolated and determined the structure of the adrenal steroids whose origins from cholesterol had not been suspected by anyone. Butenandt was able to rapidly determine the structure of estrone, androsterone, and progesterone, for which he received the Nobel Prize in 1939. Probably the climax in the extraordinary research output of Adolf Windaus was his elucidation of the structure and biosynthesis of vitamin D. Hess in New York had made the observation that ultraviolet radiation of a lipid extract in- duced the formation of active vitamin D. In the next 8 years, Adolf Windaus and his students succeeded in identifying the provitamin as ergosterol and 7-dehydrocholesterol and also in clarifying the structure of vitamin D2 and vitamin D3. The complex steps in photoactivation of the vitamin were clarified, and each intermediate was crystallized and its structure determined. Thus, the research area of the chemical structure of cholesterol, which Adolf Windaus had selected when still a young docent in Freiburg led to studies spanning over 30 years – studies which opened up a vast – almost limitless field that continues to be active today. His work has been of inestimable significance for the practice of medicine. Adolf Windaus, however, insisted that his research was not aimed at applications, but only at understanding the mysteries of nature. Adolf Windaus had a legendary reputation among his colleagues and students. He was a man of infinite energy and extraordinary insight, who could reduce scientific problems to their essence. He had the art to ask the right question and do the definitive experiment. Nature disclosed her secrets quickly to a man of such talent. His former associates had continuous admiration for his clarity of speech, both in conversation and scientific discussion. He was a man of modesty and dignity who combined the highest scientific standards with great personal generosity. For his many discoveries, Adolf Windaus received many honors and awards. Under his leadership, the Chemical Institute in Göttingen became known throughout the world. He was honored by being chosen to receive the Nobel Prize for chemistry in 1928, and his lecture is a masterpiece of erudition, clarity and modesty. W. Gerok (✝) 12
ADOLF WINDAUS AWARD
The ”Adolf Windaus Award“ was founded by the Falk Foundation e.V. and
will, for the and twenty-second, be presented on the occasion of the XXVI
International Bile Acid Meeting, on July 8, 2022. The prize amounts to
€15,000 and is awarded for outstanding contributions in the field of bile
acid research.
Members of the Prize Committee:
U. Beuers (Amsterdam)
D. Häussinger (Düsseldorf)
A. Parés (Barcelona)
R. Poupon (Paris)
M. Trauner (Vienna)
Windaus Prize Winners:
1980 - C. Einarsson (Stockholm) & K. Hellstrom (Stockholm)
1982 - E. H. Mosbach (New York) & H. Danielsson (Uppsala)
1984 - M. C. Carey (Boston)
1986 - I. Bjorkhem (Huddinge)
1988 - J. L. Boyer (New Haven)
1990 - P. B. Hylemon (Richmond) & P. J. Meier-Abt (Zurich)
1992 - K. Okuda (Hiroshima)
1994 - Z. R. Vlahcevic (Richmond)
1996 - W. Kramer (Frankfurt)
1998 - P. A. Dawson (Winston-Salem)
2000 - D. J. Mangelsdorf (Dallas)
2002 - D. W. Russell (Dallas)
2004 - K. D. R. Setchell (Cincinnati)
2006 - R. Poupon (Paris)
2008 - N. Ballatori (Rochester)
2010 - J. Auwerx & K. Schoonjans (Lausanne)
2012 - G. Paumgartner (Munich)
2014 - S. Kliewer (Dallas)
2016 - D. Keppler (Heidelberg)
2018 - B.B. Stieger (Zurich)
Coordinator of the Prize Committee:
Prof. Dr. Dieter Häussinger
Department of Internal Medicine
Clinic of Gastroenterology, Hepatology and Infectious Diseases
Heinrich-Heine-University Düsseldorf
Moorenstr. 5 | 40225 Düsseldorf | Germany
haeussin@uni-duesseldorf.de
13LIST OF SPEAKERS, MODERATORS
AND SCIENTIFIC ORGANIZERS
Prof. Dr. Ulrich Beuers Paul A. Dawson, Ph.D.
Department of Gastroenterology Professor
& Hepatology, C2-327 Division of Gastroenterology, Hepatology
Univ. van Amsterdam, Tytgat Institute and Nutrition
for Liver & Intestinal Research Emory University School of Medicine
Meibergdreef 9 Children’s Healthcare of Atlanta Research
1105 AZ Amsterdam Scholar
The Netherlands Health Sciences Research Building
u.h.beuers@amc.uva.nl 1760 Haygood Drive
Suite E200, Office E206
Dr. Francisco J. Caballero-Camino Atlanta, GA, 30322
Dept. of Medicine USA
University of the Basque Country paul.dawson@emory.edu
Dept. Of Liver and Gastrointestinal Diseases
Biodonostia Health Research Institute Ronald M. Evans, Ph.D.
Donostia University Hospital Professor of Biology
Paseo del Doctor Beguiristain The Salk Institute for Biological Studies
20014 San Sebastian Gene Expression Laboratory
Spain 10010 North Torrey Pines Road
javier.caballero@biodonostia.org La Jolla, CA 92037
USA
Dr. Clarissa Campbell evans@salk.edu
CeMM
Forschungszentrum für Molekulare Medizin Prof. Dr. Peter Fickert
der Österreichischen Akademie der Wissen- Innere Medizin I und III
schaften Medizinische Universität Graz
Lazarettgasse 14, AKH BT 25.3 Auenbruggerplatz 15
1090 Vienna 8036 Graz
Austria Austria
ccampbell@cemm.oeaw.ac.at peter.fickert@medunigraz.at
Prof. Dr. Olivier Chazouilleres Prof. Dr. Dieter Häussinger
Service d’Hépatologie Klinik für Gastroenterologie, Hepatologie
Hôpital Saint-Antoine und Infektiologie
184 rue du Faubourg Saint-Antoine Universitätsklinikum Düsseldorf
75012 Paris Moorenstr. 5
France 40225 Düsseldorf
olivier.chazouilleres@aphp.fr Germany
haeussin@uni-duesseldorf.de
14Prof. Dr. Jan G. Hengstler Prof. Jose J. G. Marin
Leibniz Research Centre for Working University of Salamanca
Environment and Human Factors Experimental Hepatology and Drug Targeting
Department Toxicology / Systems Toxicology (HEVEFARM), IBSAL, CIBEREHD
Ardeystraße 67 Campus Miguel de Unamuno, ED-Lab231
44139 Dortmund 37007 Salamanca
Germany Spain
hengstler@ifado.de jjgmarin@usal.es
Toni Herta Prof. Dr. Hanns-Ulrich Marschall
Gastroenterologie, Hepatologie, Pneumologie Dept. of Molecular and Clinical Medicine
Universitätsklinikum Leipzig University of Gothenburg
Liebigstr. 20 41345 Gothenburg
04103 Leipzig Sweden
Germany hanns-ulrich.marschall@gu.se
toni.herta@medizin.uni-leipzig.de
David D. Moore, Ph.D.
Dr. Stephen J. Keely Nutritional Sciences and Toxicology
Molecular Medicine Laboratories University of California, Berkeley
RCSI Education & Research Center 127 Morgan Hall
Smurfit Building Berkeley, CA 94720-3104
Beaumont Hospital USA
Beaumont Road daviddmoore@berkeley.edu
Dublin
Ireland Prof. Dr. Ronald P. J. Oude Elferink
skeely@rcsi.ie Univ. van Amsterdam, Tytgat Institute
for Liver & Intestinal Research
Prof. Dr. Verena Keitel Academic Medical Center S1-162
Klinik für Gastroenterologie, Hepatologie Meibergdreef 69-71
und Infektiologie 1105 BK Amsterdam
Universitätsklinikum Magdeburg The Netherlands
Leipziger Str. 44 r.p.oude-elferink@amc.uva.nl
39120 Magdeburg
Germany Dr. Fotios Sampaziotis
verena.keitel-anselmino@med.ovgu.de Cambridge Stem Cell Institute, Jeffrey
Cheah Biomedical Centre
Isabell Leclercq University of Cambridge
UCLouvain Puddicombe Way
School of Medicine and Institute for Cambridge Biomedical Campus
Experimental and Clinical Research CB2 0AW
Brussels Great Britain
Belgium fs347@cam.ac.uk
isabelle.leclercq@uclouvain.be
15Prof. Dr. Lutz Schmitt Prof. Dr. Stan van de Graaf
Institut für Biochemie I Univ. van Amsterdam, Tytgat Institute
Heinrich-Heine-Universität for Liver & Intestinal Research
Universitätsstr. 1 / Gebäude 26.44 Meibergdreef 69-71
40225 Düsseldorf 1105 BK Amsterdam
Germany The Netherlands
lutz.schmitt@hhu.de k.f.vandegraaf@amc.uva.nl
Prof. Dr. Bernd Schnabl Prof. Dr. Saskia W. C. van Mil
Division of Gastroenterology Center for Molecular Medicine
UC San Diego School of Medicine UMC Utrecht
9500 Gilman Drive Universiteitsweg 100
La Jolla, CA 92093 3584CG Utrecht
USA The Netherlands
beschnabl@health.ucsd.edu s.w.c.vanmil@umcutrecht.nl
Prof. Richard J. Thompson
PD Dr. Martin Wagner
King’s College Hospital Institute of Liver
Klinische Abteilung für Gastroenterologie
Studies
und Hepatologie
Denmark Hill
Medizinische Universität Graz
London SE5 9RS
Auenbruggerplatz 15
Great Britain
8036 Graz
richard.j.thompson@kcl.ac.uk
Austria
martin.wagner@medunigraz.at
Prof. Dr. Michael Trauner
Klinische Abteilung für
Prof. Dr. Catherine Williamson
Gastroenterologie & Hepatologie
Department of Women‘s Health
Medizinische Universität Wien
King‘s College London
Währinger Gürtel 18-20
Hodgkin Building
1090 Wien
Newcomen Street
Austria
London SE1 1UL
michael.trauner@meduniwien.ac.at
Great Britain
catherine.williamson@kcl.ac.uk
Prof. Dr. Stephan Urban
Molecular Virology
Prof. Huiping Zhou, PhD
University of Heidelberg
The Huiping Zhou Laboratory
Im Neuenheimer Feld 344
Molecular Medicine Research Building
69120 Heidelberg
Room 5-044
Germany
1220 E Broad Street
stephan.urban@med.uni-heidelberg.de
Richmond VA 23298
USA
huiping.zhou@vcuhealth.org
16POSTER SESSION
Posters will be exhibited on July 8-9, 2022. The authors will be in attend-
ance during coffee and lunch breaks on both days. Posters can be set up
starting on Friday, July 8, 2022 at 10:00 h. We request that all posters be
set up on Friday before noon.
CALL FOR POSTERS
Please submit your poster abstract thematically related to one of
before April 30, 2022. Only one- the sessions of the congress. The
page abstracts not exceeding 300 accepted abstracts will be printed
words, written in English and saved and distributed to congress
in Microsoft Word format will be participants along with the other
accepted. meeting information.
Abstracts must be submitted via Poster authors will receive notifica-
our Internet Abstract Submission tion about acceptance and further
System (https://poster.falkfoun- instructions in May 2022.
dation.com) where further infor-
mation regarding the submission For the first author of an accepted
format and the submission process poster, accomodation expenses
is available. (July 8-10, 2022) and fees for the
scientific program will be covered
The abstracts will be selected during Symposium 229. Travel ex-
by the scientific organizers, with penses will not be
preference being given to those covered.
POSTER AWARDS
Three prizes will be awarded for the best poster presentations. Winners
will be asked to give a short presentation (2 – 5 minutes) of their poster
during the award ceremony.
Award winners will be presented with a certificate and prize money of
EUR 1500, EUR 1000 and EUR 500.
Travel expenses will also be covered for the first authors of the three
winning posters.
17REGISTRATION You can register for the event via our homepage: www.falkfoundation.org Registration is only possible online. CONGRESS FEES Scientific Program of Symposium 229 EUR 300 Students (copy of student ID required) EUR 150 The congress fees include: – Networking with light refreshments on Thursday, July 7, 2022 – Refreshments during coffee breaks – Lunch on Friday, July 8 and on Saturday, July 9, 2022 – Snacks during scientific discussion on Friday, July 8, 2022 – A copy of the final program CONGRESS OFFICE AND REGISTRATION Opening Hours: Thursday, July 7, 2022 8:00 – 18:00 h Friday, July 8, 2022 7:30 – 18:00 h Saturday, July 9, 2022 8:30 – 17:00 h 18
ARRIVAL
Beurs van Berlage
Damrak 243
1012 ZJ Amsterdam
The Netherlands
Amsterdam Conference Centre Beurs van Berlage is located in the center
of Amsterdam, on the Damrak, Oude Brugsteeg and Beursstraat, directly
facing Amsterdam Central Station, at a short distance of highways and
Schiphol airport.
By car
In the vicinity of Beurs van Berlage you will find several car parks, but
the ideal way to reach the city centre of Amsterdam is to park the car at
P+R location at the edge of the city and use public transportation. If you
come from the northeast, east or southeast of the Netherlands, it is best
to use the P+R Zeeburg. Accessible via Ring A10, exit S114. If you come
from the northwest or west of the Netherlands, it is best to park at P+R
Sloterdijk, which is accessible via Ring A10, exit S103.
By plane
From Amsterdam Schiphol Airport, you can get to Beurs van Berlage by train
or taxi. If you are travelling by train, it is best to buy a ticket to Amsterdam
Centraal Station in the Arrivals Hall of Schiphol. The trains leave four times
per hour and the journey takes about fifteen minutes. Should you wish to take
a taxi, you can state “Beurs van Berlage” as your destination. The address is:
Damrak 243. The drive takes about twenty-five minutes (approx. 20 km).
By train
Beurs van Berlage is located 300 metres away from Amsterdam Centraal
Station, which is a 5 min walking distance. You can see Beurs van Berlage on
the Damrak in front of you after leaving Central Station along the Stations-
plein (station square) and head out towards the Dam from there.
1920
Registration via www.falkfoundation.org
or simply scan and participate.
Together we know more. Together we do more.
Falk Foundation e.V. | Leinenweberstr. 5 | 79108 Freiburg | Germany
T: +49 761 15 14 440 | F: +49 761 15 14 460 | E-Mail: meeting@falkfoundation.org
www.falkfoundation.orgYou can also read
